Zacks: Evotec AG (NASDAQ:EVTCY) Given Consensus Rating of “Strong Buy” by Analysts
Evotec AG (NASDAQ:EVTCY) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Zacks has also given Evotec AG an industry rank of 88 out of 265 based on the ratings given to related companies.
Several equities analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Evotec AG from a “hold” rating to a “strong-buy” rating and set a $11.00 price objective on the stock in a research note on Friday, August 12th. DZ Bank AG reaffirmed a “buy” rating on shares of Evotec AG in a research note on Monday, July 11th.
Shares of Evotec AG (NASDAQ:EVTCY) opened at 10.47 on Monday. The firm has a market cap of $693.89 million and a price-to-earnings ratio of 118.98. The stock has a 50 day moving average of $9.85 and a 200 day moving average of $8.56. Evotec AG has a 52-week low of $6.56 and a 52-week high of $10.60.
About Evotec AG
Evotec AG (Evotec) is a drug discovery and development company. The Company is engaged in providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors. The Company has two segments: EVT Execute and EVT Innovate. EVT Execute segment offers stand-alone or integrated drug discovery solutions for collaborator’s targets and programs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.